Latest news, reports, and more from the RedChip Nation.
 
What’s Next for Small Caps Amid Growing Market Turmoil?
 
 

Major stock indices are back in the red for the year, erasing what at one point just a few weeks ago were sizeable gains.

 

The small-cap Russell 2000, once the leader of the major indexes this year, has led in the most recent decline.

 

Barron’s and other publications that touted the safe-haven status of small-caps amid growing tariffs and trade wars have now begun to question their outlook moving forward.

 

What should a small-cap investor do?

 

First, don’t panic.

 

The bullish momentum in the broader global equity markets leading into this year was strong enough that the near-term outlook is more likely a trading range than an impending bear market.

 

More importantly, as a small-cap investor, while the Russell 2000 may play a role in your asset allocation for your less risky growth assets, the real money is made in finding undervalued and underfollowed stocks poised to catch Wall Street’s interest.

 

The Russell 2000 will never return triple digits in a year, but by finding the right small-caps, and building your own diversified basket of six to even 10 small-cap stocks, you could not only significantly outperform the index, but you could also positively hedge your larger holdings.

 

As an example, right here from the RedChip Nation, when the broader markets fell sharply two weeks ago, we had multiple stocks that posted double-digit gains for the week.

 

Marker Therapeutics (NASDAQ: MRKR) was up 22% that week. MamaMancini’s Holdings (OTCQB: MMMB) was up 18%. And SuperCom (NASDAQ: SPCB) was up nearly 11%, just to name a few.

 

Last week, as the markets closed even lower, RedChip Nation stocks again bucked the broader trends, including 1347 Property (NASDAQ: PIH) up 10% and Craft Brew Alliance (NASDAQ: BREW) up 8%.

 

So the best course of action for most would be to dollar-cost average into your index ETFs while the market is down for your lower risk money, and for your higher risk allocations, continue to search for exciting small caps with big potential, led by strong management teams, that haven’t quite reached Wall Street’s radar screen yet.

 

And of course, reading the RedChip Money Report and watching our exclusive CEO interviews are great ways to stay abreast of the latest developments on what could become future homeruns in the small-cap space.

 
  365 words
 
 
 
 
 
 >
Marker Therapeutics (NASDAQ: MRKR) Strengthens Management Team
 
 

Marker Therapeutics (NASDAQ: MRKR), a clinical-stage immuno-oncology company, announced the addition of four senior executives to its executive management team last week.

 

Key Quote: "Together, our new executives add over 75 years of cumulative experience in advancing cell therapies and immunotherapies that can change patients' lives. We are excited and fortunate to have these four highly accomplished professionals join our team." Peter L. Hoang, President & CEO

 

What’s Next: Marker Therapeutics is advancing a pipeline of next-generation, non-gene-modified multi-antigen specific T cell therapies for the treatment of blood cancers and solid tumors, both multi-billion opportunities. With the addition of key executives with subject-specific expertise, Marker Therapeutics is well on its way to achieving success.

 

Disclosure

Marker Therapeutics Inc. (NASDAQ: MRKR) is a client of RedChip Companies, Inc. MRKR agreed to pay RedChip Companies, Inc., a monthly cash fee for (4) months of RedChip investor awareness services.

 
 
 
 
Intel (NASDAQ: INTC) Generates Better-than-Expected Q3 Earnings
 
 

Intel (NASDAQ: INTC) posted adjusted EPS of $1.40 in the third quarter, higher than analysts’ expectation of $1.15. Its earnings also increased 39.0% YoY (year-over-year). Strong revenues, higher operating margins, and a lower tax rate drove earnings growth in the quarter.

 

On a per-share basis, the Santa Clara, California-based company said it had net income of $1.38. Earnings, adjusted for one-time gains and costs, were $1.40 per share.

 

The results beat Wall Street expectations. The average estimate of 15 analysts surveyed by Zacks Investment Research was for earnings of $1.15 per share.

 

The world's largest chipmaker posted revenue of $19.16 billion in the period, also beating Street forecasts. Thirteen analysts surveyed by Zacks expected $18.11 billion.

 

 
 
 
 >
Anavex Life Sciences (NASDAQ: AVXL) Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett’s Syndrome
 
 

Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett’s syndrome and other central nervous system (CNS) diseases, has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for ANAVEX®2-73 for the treatment of Rett’s syndrome, a rare and catastrophic neurodevelopmental disease.

 

Why It Matters: ANAVEX®2-73 has already received orphan drug designation from the FDA for the treatment of Rett’s syndrome.

 

The Backstory: Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett’s syndrome, and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73, recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.

 

 
 
 
 >
Growth May Slow a Bit More in Q4 but Still Finish Around 3% for 2018: Kevin Hassett, Trump Economic Advisor
 
 

Speaking to CNBC on Monday, Kevin Hassett, an economic advisor to President Donald Trump, said he expects economic growth to slow again in the fourth quarter.

 

Last week, the federal government's first estimate of third-quarter gross domestic product showed a faster-than-expected annual growth rate of 3.5%.

 

Hassett refused to offer advice about how central banks should act on interest rates, as the Federal Reserve considers raising interest rates for a fourth time this year.

 

Recent market turmoil has suffered wild swings and the Fed under Chairman Jerome Powell has faced sharp criticism from Trump for raising interest rates. Trump has argued that stronger growth in the economy is not causing problematic inflation

 

 
 
 
 >
Oil Prices Fall As Concern Deepens over Global Economic Outlook
 
 

Oil prices dropped on Monday as concern over the global economy put crude on track for its biggest monthly fall since mid-2016.

 

Even with U.S. sanctions on Iranian exports due to come into force in under a week, both contracts are on pace for their largest percentage decline since July 2016.

 

With renewed sanctions on the horizon, India, China, and Turkey are resisting U.S. sanctions and have argued that there are not sufficient suppliers to replace them.

 

 
 
 
 
Quote of the Week
 
"With cash, a company can survive tough times, a bad economic environment. Cash provides an anchor to valuation."
-Dave Maley, Manager Ariel Discovery Fund
 
 
 
Lesson of the Week
 
Don't let emotions drive your investment decisions.
Read More
 
 
 
 
Latest Videos
 
 
 
 
Catasys, Inc.(NASDAQ: CATS) Solution (OnTrak) Reduces Medical Costs by 54% for Enrolled Members
 
Watch Now
 
 
 
 
Galaxy Next Generation (OTCQB: GAXY) Fast Growing EdTech Company
 
Watch Now
 
 
 
 
PHI Group (OTCQB: PHIL) Corporate Video Highlighting Growth Plans
 
Watch Now
 
 
 
 
This Telecom Trading at Discount to Peers
 
Watch Now
 
 
 
 
MamaMancini’s: Marketer & Distributor of All Natural Italian Specialty Prepared Foods
 
Watch Now
 
 
 
 
Opsens Webinar
 
Watch Now
 
 
 
 
MamaMancini’s: Marketer & Distributor of All Natural Italian Specialty Prepared Foods
 
Watch Now
 
 
 
 
This Week on RedChip TV: Three High-Growth Healthcare Stocks
 
Watch Now
 
 
 
 
Immuron: Developing Innovative Immunotherapy Therapies for Gut-Mediated Diseases
 
Watch Now
 
 
 
 
Opsens Has Treated 40,000 Patients Using Cutting-edge FFR technology in 30+ countries
 
Watch Now
 
 
 
 
Opsens Operates in the $500M+ Fractional Flow Reserve (FFR) Market
 
Watch Now
 
 
 
 
PHI Group: Fast-growing Company Enhancing Shareholder Value Through Mergers and Acquisitions
 
Watch Now
 
 
 
 
Nemaura Medical's (NMRD) SugarBEAT® Technology Targets Billion Dollar Opportunity
 
Watch Now
 
 
 
 
Nemaura (NMRD) Set to Launch SugarBEAT® CGM to All Diabetics, Pre-Diabetics & Insulin-Users
 
Watch Now
 
 
 
 
Level Brands: Fast-Growing, High-Margin Licensing & Brand Management Company
 
Watch Now
 
 
 
 
Immuron: Developing Innovative Immunotherapy Treatments for a Variety of Diseases
 
Watch Now
 
 
 
 
GSRX Industries: Growing MJ Business Led by Former Chairman & CEO of Macy's Midwest
 
Watch Now
 
 
 
 
 
 
 
 
Order Small Stocks, Big Money Today!
 
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
 
 
MidSouth Week in Review
 
The S&P 500 is on track to have its worst month since 2011.
Read More
 
 
 
Top Movers of the Week
 
PIH led the Nation stocks higher last week, up 10%.
Read More
 
 
Weekly Index Performance
 
Major indexes declined sharply last week, losing as much as 4%.
Read More
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
 
RedChip Disclosure
 
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
 
 
     
 
 
Copyright © 2018 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
If you received this email by mistake you can
unsubscribe from all emails.